In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

Executive Summary

The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.

You may also be interested in...



Regeneron And Geisinger Get Ambitious In Next-Gen Genomics

Regeneron and Geisinger’s new collaboration to identify genetic variants and apply that knowledge to drug discovery and patient care is pharma’s most ambitious effort to date to exploit next-generation genomics, but its impact on drug discovery productivity won’t be known for years.

Debate At PSA 2013: Can ‘Dream Team’ Approach To Scientific Innovation Work for Big Pharma?

How best to tap scientific innovation? Identifying the top ‘true’ innovators and nurturing them and their ideas in-house may work for biotechs like Regeneron, but the fruits of such efforts are too rare to be reliable growth engines for big companies like Pfizer. That’s one takeaway from a lively R&D chiefs debate at Elsevier’s PSA 2013.

Building A Fully Integrated Biotech Company: What It Takes

A typical mature biotech company evolves over four discrete stages – from the initial discovery stage through the preclinical and early clinical stage, then to the late clinical trials and commercial build-out – before it becomes a fully integrated biotech company. The final transition is a make-or-break scenario for any biotech company, and high-quality marketed products alone don’t guarantee a successful transformation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV003808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel